> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# OND Expands Regulatory Science Research
- URL: https://www.fdaweb.com/ond-expands-regulatory-science-research/
- Published: 2023-04-18T12:00:00.000Z
- Updated: 2026-09-14T18:26:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154241

The CDER Office of New Drugs (OND) Regulatory Research Program, which was started in 2018 to centralize and create an infrastructure for OND regulatory science research, recently published its first two fiscal year annual reports. Research Program associate director **Laura Jaeger** says in an online [post](https://www.fda.gov/drugs/news-events-human-drugs/office-new-drugs-efforts-expand-regulatory-science-research?utm%5Fmedium=email&utm%5Fsource=govdelivery) the reports “are a celebration of how we contributed to the field of regulatory research, which is research to help our agency make informed, evidence-based regulatory decisions.”

According to Jaeger, regulatory science research is much more targeted than basic scientific research, which provides fundamental knowledge about the nature and behavior of living systems. “The OND research program is focused on addressing specific scientific questions that will produce immediate impacts on how CDER and FDA make drug approval decisions,” she writes. “Because our research is targeted, our projects are relatively short, about three to four years.”

The program funds both extramural (investigators from outside FDA) and intramural (FDA investigators) research, Jaeger says. The post cites examples of both types of research taken from the two annual reports.